Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This randomized phase III trial is studying combination chemotherapy followed by surgery and
two different combination chemotherapy regimens with or without PEG-interferon alfa-2b to
compare how well they work in treating patients with osteosarcoma. Drugs used in chemotherapy
work in different ways to stop the growth of tumor cells, either by killing the cells or by
stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill
more tumor cells. Biological therapies, such as PEG-interferon alfa-2b, may interfere with
the growth of tumor cells. Giving combination chemotherapy before surgery may shrink the
tumor so it can be removed. Giving combination chemotherapy together with PEG-interferon
alfa-2b after surgery may kill any remaining tumor cells. It is not yet known whether giving
combination therapy together with PEG-interferon alfa-2b is more effective than two different
combination chemotherapy regimens alone after surgery in treating osteosarcoma.
Phase:
Phase 3
Details
Lead Sponsor:
Children's Oncology Group
Collaborators:
National Cancer Institute (NCI) University College London Hospitals